Moderna: Can be an interesting entry point
The Company will increase the number of participants in the study on the effectiveness of the vaccine on children between 6 months to 12 years old.
In previous reports from the end of July, the company announced that 7,000 participants would participate in the study and now it is reported that following the FDA requirement, the company will increase the number of participants in the trial to 13,275.
The company’s stock is down 15% in New York.
Stock Price Target (Wall Street Journal)
High $463.00
Median $271.50
Low $85.00
Average $290.83
